Rani Therapeutics Statistics
Share Statistics
Rani Therapeutics has 57.43M shares outstanding. The number of shares has increased by 105.4% in one year.
| Shares Outstanding | 57.43M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 5.43% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 39.36M |
| Failed to Deliver (FTD) Shares | 9.10K |
| FTD / Avg. Volume | 0.5% |
Short Selling Information
The latest short interest is 1.49M, so 2.6% of the outstanding shares have been sold short.
| Short Interest | 1.49M |
| Short % of Shares Out | 2.6% |
| Short % of Float | 3.84% |
| Short Ratio (days to cover) | 0.36 |
Valuation Ratios
The PE ratio is -2.49 and the forward PE ratio is -2.54.
| PE Ratio | -2.49 |
| Forward PE | -2.54 |
| PS Ratio | 0 |
| Forward PS | 21.6 |
| PB Ratio | 6.58 |
| P/FCF Ratio | -1.61 |
| PEG Ratio | n/a |
Enterprise Valuation
Rani Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 6.36, with a Debt / Equity ratio of 2.34.
| Current Ratio | 6.36 |
| Quick Ratio | 6.36 |
| Debt / Equity | 2.34 |
| Total Debt / Capitalization | 70.05 |
| Cash Flow / Debt | -1.7 |
| Interest Coverage | -13 |
Financial Efficiency
Return on equity (ROE) is -2.64% and return on capital (ROIC) is -119.01%.
| Return on Equity (ROE) | -2.64% |
| Return on Assets (ROA) | -0.59% |
| Return on Capital (ROIC) | -119.01% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -242.64K |
| Employee Count | 140 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -41.9% in the last 52 weeks. The beta is 0.11, so Rani Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.11 |
| 52-Week Price Change | -41.9% |
| 50-Day Moving Average | 2.24 |
| 200-Day Moving Average | 3.49 |
| Relative Strength Index (RSI) | 29.04 |
| Average Volume (20 Days) | 1.81M |
Income Statement
In the last 12 months, Rani Therapeutics had revenue of $0 and earned -$33.97M in profits. Earnings per share was $-1.33.
| Revenue | 0 |
| Gross Profit | -822.00K |
| Operating Income | -66.10M |
| Net Income | -33.97M |
| EBITDA | -65.28M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.33 |
Balance Sheet
The company has $5.86M in cash and $30.10M in debt, giving a net cash position of -$24.23M.
| Cash & Cash Equivalents | 5.86M |
| Total Debt | 30.10M |
| Net Cash | -24.23M |
| Retained Earnings | -72.89M |
| Total Assets | 43.54M |
| Working Capital | 12.16M |
Cash Flow
In the last 12 months, operating cash flow was -$51.24M and capital expenditures -$1.23M, giving a free cash flow of -$52.47M.
| Operating Cash Flow | -51.24M |
| Capital Expenditures | -1.23M |
| Free Cash Flow | -52.47M |
| FCF Per Share | -2.06 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
RANI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -80.61% |
| FCF Yield | -55.37% |
Analyst Forecast
The average price target for RANI is $9.5, which is 475.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.5 |
| Price Target Difference | 475.8% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -4.8 |
| Piotroski F-Score | 2 |